Drug Trial Radar · NCT01114529
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Last checked: Nov 20, 2026Latest source record: May 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
828
Actual
Start
Aug 9, 2010
Primary completion
Oct 30, 2014
Study completion Oct 30, 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients
Conditions
- Kidney Transplantation
Interventions
EverolimusDrug
Early CNI to everolimus conversion
Prograf or NeoralDrug
Active CNI-based control (Prograf or Neoral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Glomerular Filtration Rate (eGFR)Time frame: Month 12
Locations
77 sites in 21 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
San Martín, Buenos Aires, Argentina
Novartis Investigative Site
Resistencia, Chaco Province, Argentina
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Tartu, Estonia
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Tours, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Frankfurt am Main, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hannover Muenden, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Pátrai, Greece, Greece
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Visakhapatnam, Andhra Pradesh, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Padova, PD, Italy
Novartis Investigative Site
Roma, RM, Italy
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.